Neurologist Michelle Monje studies the close relationship between cancer and the nervous system, particularly in an aggressive brain cancer that often strikes in childhood. Her research shows that the cancer cells are electrically integrated into the brain itself and these connections actually help the cancer to grow. Monje and collaborators have now developed an immunotherapy that has shown great promise in mice and early human trials. One patient had a “complete response” and is cancer-free four years after treatment, Monje tells host Russ Altman on this episode of Stanford Engineering’s The Future of Everything podcast.

Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to [email protected].

Episode Reference Links:

• Stanford Profile: Michelle Monje

Connect With Us:

• Episode Transcripts >>> The Future of Everything Website
• Connect with Russ >>> Threads / Bluesky / Mastodon
• Connect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / Facebook

Chapters:

(00:00:00) Introduction

Russ Altman introduces guest Michelle Monje, a professor of pediatric neurology at Stanford University.

(00:03:39) Focus on Cancer Research

Monje’s clinical observations led to exploring cancer-neuron interactions.

(00:05:28) Neurons and Glial Cells

The role of neurons and glial cells in brain function and disease.

(00:08:32) Gliomas in Children

An overview of gliomas and their origins in glial precursor cells.

(00:10:12) Rethinking Brain Cancer Behavior

How gliomas don’t just grow—they integrate with brain circuits.

(00:14:49) Mechanisms of Tumor Growth

Two primary mechanisms by which cancer exploits the nervous system.

(00:16:32) Synaptic Integration of Cancer Cells

The discovery that glioma cells form synapses with neurons.

(00:20:06) CAR T-Cell Therapy

Adapting CAR T-cell immunotherapy to target brain tumors.

(00:22:52) Targeting GD2 Antigen

Identification of a surface marker enables precision CAR T-cell therapy.

(00:24:35) Immune Access to the Brain

The ability of CAR T-cells to reach the brain, despite prior understanding.

(00:26:16) First Clinical Trial Results

The significant tumor reduction and response from CAR T-cell therapy.

(00:28:21) Combined Therapies

Pairing immune therapy with neural signaling blockers for better outcomes.

(00:30:35) Conclusion

Connect With Us:

Episode Transcripts >>> The Future of Everything Website

Connect with Russ >>> Threads / Bluesky / Mastodon

Connect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.